CARVYKTI achieves $657M in Q2 2026 sales, up 50% year-over-year

Legend Biotech / Johnson & Johnson/CARVYKTI (cilta-cel)

CARVYKTI generated $657 million in net trade sales during Q2 2026, representing 50% growth compared to Q2 2025. The therapy is now available across 348 treatment sites in 19 global markets, making it the best-selling CAR-T in the world.

• Q2 2026 sales of $657 million, up 50% year-over-year
• Global expansion to 348 treatment sites across 19 markets
• Ireland launch in Q2 2026 expands European presence
• First-generation CAR-T sales growth exceeds all competitors